The company’s financial results for the second quarter of 2026 reflect this commercial momentum, with net sales climbing 66% to 717,000 euros. Operating losses narrowed to 4.2 million euros compared to 4.5 million in the same period last year. A key driver of this growth is the strengthening of clinical and health-economic evidence, highlighted by a major study published in Nature’s Scientific Reports. The research, which tracked 602 patients across 22 centers, reported reoperation and serious safety event rates below 2%.
Implantica Eyes US Expansion Following FDA RefluxStop Approval
With FDA approval for its RefluxStop device now secured, Vaduz-based Implantica is shifting its focus toward a full-scale U.S. market entry. The company reported a 60% surge in second-quarter sales, bolstered by new clinical data and a growing network of European Centers of Excellence.
Following the close of the quarter, Implantica cleared a significant regulatory hurdle by securing FDA Premarket Approval for RefluxStop, a device designed to treat gastroesophageal reflux disease. Management is now prioritizing the establishment of U.S. logistics and distribution infrastructure. Meanwhile, the European footprint continues to widen, reaching over 60 centers following recent expansions in Spain, Switzerland, and the UK. With 41.7 million euros in cash and equivalents, the firm enters the second half of the year positioned to scale its wireless energizing and eHealth platform technologies.
Comments (0)
No comments yet. Be the first!